151 related articles for article (PubMed ID: 31766065)
21. Lymph Node Assessment in Prostate Cancer: Evaluation of Iodine Quantification With Spectral Detector CT in Correlation to PSMA PET/CT.
Lennartz S; Täger P; Zopfs D; Iuga AI; Reimer RP; Zäske C; Große Hokamp N; Maintz D; Heidenreich A; Drzezga A; Kobe C; Persigehl T
Clin Nucl Med; 2021 Apr; 46(4):303-309. PubMed ID: 33443954
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
23. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N
Future Oncol; 2021 Jun; 17(17):2225-2241. PubMed ID: 33724868
[TBL] [Abstract][Full Text] [Related]
24. An
Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
[TBL] [Abstract][Full Text] [Related]
25. Thrombosis of the Iliac Vein Detected by 64Cu-Prostate-Specific Membrane Antigen (PSMA) PET/CT.
Annunziata S; Rea S; Romano L; Mazzone C; Di Traglia S; Sciuto R
Clin Nucl Med; 2021 Jan; 46(1):e29-e30. PubMed ID: 33031241
[TBL] [Abstract][Full Text] [Related]
26. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
Iagaru A
J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
[No Abstract] [Full Text] [Related]
27. Schmorl's Node: Confusion Still Persists in 68Ga-Prostate-Specific Membrane Antigen Ligand PET/CT.
Sahoo MK; Ahlawat K; Yadav R; Gajendra S
Clin Nucl Med; 2018 Sep; 43(9):679-681. PubMed ID: 30036258
[TBL] [Abstract][Full Text] [Related]
28. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
[TBL] [Abstract][Full Text] [Related]
29. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
30. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer.
Ravi Kumar AS; Lawrentschuk N; Hofman MS
Curr Opin Urol; 2020 Sep; 30(5):628-634. PubMed ID: 32701720
[TBL] [Abstract][Full Text] [Related]
32. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
[No Abstract] [Full Text] [Related]
33. Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption.
Hofman MS
J Nucl Med; 2020 Dec; 61(Suppl 2):246S-247S. PubMed ID: 33293445
[No Abstract] [Full Text] [Related]
34. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
Panebianco V
Eur Radiol; 2024 Jun; 34(6):4014-4016. PubMed ID: 38165433
[No Abstract] [Full Text] [Related]
36. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
37. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
38. PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
Unterrainer LM; Ruchalski K; Allen-Auerbach MS; Calais J; Benz MR
J Nucl Med; 2024 May; 65(5):818-819. PubMed ID: 38176724
[No Abstract] [Full Text] [Related]
39. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
40. Writing PET into existence.
Chiti A; Kirienko M; Incerti E; Picchio M
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):7-10. PubMed ID: 24072349
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
